What UnitedHealth Investors Are Talking About Today.

By Kim Brooks • Friday, November 17 15:20 • Permanent Link

UnitedHealth logged a -0.8% change during today's afternoon session, and is now trading at a price of $535.51 per share. The S&P 500 index moved 0.0%. UNH's trading volume is 1,594,017 compared to the stock's average volume of 2,706,273.

UnitedHealth trades -2.16% away from its average analyst target price of $547.32 per share. The 23 analysts following the stock have set target prices ranging from $497.49 to $608.04, and on average have given UnitedHealth a rating of buy.

Anyone interested in buying UNH should be aware of the facts below:

UnitedHealth has moved 2.0% over the last year, and the S&P 500 logged a change of 15.0%
Based on its trailing earnings per share of 23.05, UnitedHealth has a trailing 12 month Price to Earnings (P/E) ratio of 23.2 while the S&P 500 average is 15.97
UNH has a forward P/E ratio of 20.8 based on its forward 12 month price to earnings (EPS) of $25.71 per share
The company has a price to earnings growth (PEG) ratio of 2.01 — a number near or below 1 signifying that UnitedHealth is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 5.86 compared to its sector average of 4.16
UnitedHealth Group Incorporated operates as a diversified health care company in the United States.
Based in Minnetonka, the company has 400,000 full time employees and a market cap of $495.31 Billion. UnitedHealth currently returns an annual dividend yield of 1.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.